Capmatinib

  • TRADE NAME: Tabrecta (Novartis)
  • INDICATIONS:

    Metastatic non-small cell lung cancer in adult patients.

    NOTE: (2020) FDA approved under accelerated approval based on overall response rate and duration of response. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trial(s). 


  • SYNONYM: Capmatinib hydrochloride
  • CLASS: Kinase inhibitor, MET (mesenchymal-epithelial transition) inhibitor
  • HALF-LIFE: 6.5 hours

FDA APPROVAL DATE: 05/06/2020

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

CYP3A inducers, CYP3A inhibitors, Itraconazole, Rabeprazole, Rifampin


Can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception.

Our database has 28 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.


Page last updated 02/10/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top